Multimodal, PSMA-Targeted, PAMAM Dendrimer-Drug Conjugates for Treatment of Prostate Cancer: Preclinical Evaluation
DOI: https://doi.org/10.2147/ijn.s454128
IF: 7.033
2024-05-30
International Journal of Nanomedicine
Abstract:Wojciech G Lesniak, 1 Srikanth Boinapally, 1 Gabriela Lofland, 1 Zirui Jiang, 1 Catherine A Foss, 1 Babak Behman Azad, 1 Anna Jablonska, 1, 2 Mauro A Garcia, 1 Maria Brzezinski, 1 Martin G Pomper 1, 3 1 Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, MD, 21287, USA; 2 Institute for Cell Engineering, Johns Hopkins University, Baltimore, MD, 21218, USA; 3 Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX, 75390, USA Correspondence: Wojciech G Lesniak, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University, 600 N. Wolfe Street, Baltimore, MD, 21287, USA, Email Introduction: Prostate cancer (PC) is the second most common cancer and the fifth most frequent cause of cancer death among men. Prostate-specific membrane antigen (PSMA) expression is associated with aggressive PC, with expression in over 90% of patients with metastatic disease. Those characteristics have led to its use for PC diagnosis and therapies with radiopharmaceuticals, antibody-drug conjugates, and nanoparticles. Despite these advancements, none of the current therapeutics are curative and show some degree of toxicity. Here we present the synthesis and preclinical evaluation of a multimodal, PSMA-targeted dendrimer-drug conjugate (PT-DDC), synthesized using poly(amidoamine) (PAMAM) dendrimers. PT-DDC was designed to enable imaging of drug delivery, providing valuable insights to understand and enhance therapeutic response. Methods: The PT-DDC was synthesized through consecutive conjugation of generation-4 PAMAM dendrimers with maytansinoid-1 (DM1) a highly potent antimitotic agent, Cy5 infrared dye for optical imaging, 2,2′,2"-(1,4,7-triazacyclononane-1,4,7-triyl)triacetic acid (NOTA) chelator for radiolabeling with copper-64 and positron emission tomography tomography/computed tomography (PET/CT), lysine-urea-glutamate (KEU) PSMA-targeting moiety and the remaining terminal primary amines were capped with butane-1,2-diol. Non-targeted control dendrimer-drug conjugate (Ctrl-DDC) was formulated without conjugation of KEU. PT-DDC and Ctrl-DDC were characterized using high-performance liquid chromatography, matrix assisted laser desorption ionization mass spectrometry and dynamic light scattering. In vitro and in vivo evaluation of PT-DDC and Ctrl-DDC were carried out in isogenic human prostate cancer PSMA + PC3 PIP and PSMA − PC3 flu cell lines, and in mice bearing the corresponding xenografts. Results: PT-DDC was stable in 1×PBS and human blood plasma and required glutathione for DM1 release. Optical, PET/CT and biodistribution studies confirmed the in vivo PSMA-specificity of PT-DDC. PT-DDC demonstrated dose-dependent accumulation and cytotoxicity in PSMA + PC3 PIP cells, and also showed growth inhibition of the corresponding tumors. PT-DDC did not accumulate in PSMA − PC3 flu tumors and did not inhibit their growth. Ctrl-DDC did not show PSMA specificity. Conclusion: In this study, we synthesized a multimodal theranostic agent capable of delivering DM1 and a radionuclide to PSMA + tumors. This approach holds promise for enhancing image-guided treatment of aggressive, metastatic subtypes of prostate cancer. Keywords: prostate cancer, PSMA, PAMAM dendrimer, targeted cancer treatment, theranostics Graphical Prostate cancer (PC) is the most frequently diagnosed non-cutaneous cancer and the second most common cause of cancer-related death in men in the United States. 1 Patients with metastatic, castration-resistant PC (mCRPC) experience significant debilitation and often require aggressive treatments, negatively affecting their quality of life. Early detection of aggressive PC and the attendant earlier selection of appropriate treatment increases the survival rate. 2–4 Non-invasive molecular imaging and image-guided therapies are being increasingly employed in cancer management. Imaging of prostate-specific membrane antigen (PSMA) expression is being evaluated extensively, as it is overexpressed in most PCs, enabling their detection and treatment. 5–7 PSMA has been leveraged for diagnosis, radiopharmaceutical therapy and targeted drug delivery by low-molecular-weight agents, antibody-drug conjugates (ADCs) and polylactic acid-polyethylene glycol (PLA-PEG)-based BIND-014 nanoparticles. 5,6,8–12 Positron emission tomography/computed tomography (PET/CT) imaging with PSMA-specific radiotracers, such as recently approved [ 18 F]DCFPyL (PYLARIFY ® ), is the preferred ima -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology